1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E4CA324FD598953C652583F500434359
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-how-medical-affairs-can-drive-successful-medical-device-product-launch-staffing-investment-role-clinical-specialists?opendocument
18
19opendocument
2018.97.14.91
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Launch Optimization

How Medical Affairs Can Drive a Successful Medical Device Product Launch: Staffing, Investment & Role of Clinical Specialists

ID: 5559


Features:

10 Info Graphics

12 Data Graphics

210+ Metrics

7 Narratives


Pages/Slides: 31


Published: 2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “How Medical Affairs Can Drive a Successful Medical Device Product Launch: Staffing, Investment & Role of Clinical Specialists”

STUDY OVERVIEW

The slow shift toward real world evidence in the medical device industry and the intense competition in the device sector have pushed the Medical Affairs function into a prominent launch role that extends from the pre-launch phases to well beyond market entry.

However, the success of Medical Affairs’ launch involvement is tied, in part, to its resources. Without adequate funding and staffing, the Medical Affairs function is challenged to effectively execute all the different activities it is involved with in a new device launch.

Best Practices, LLC undertook this benchmarking research to deliver insights into how Medical Affairs field teams can provide high-value support for the launch of device products. In particular, this study delves into staffing levels of field medical teams, role and value of clinical specialists, and investment allocation to key Medical Affairs sub-functions.

This study will help Medical Affairs teams identify and implement more effective practices, pinpoint staffing/investment gaps, and inform strategic planning for new medical device product launch.

KEY TOPICS
  • Role and value of clinical specialists
  • MSL & clinical specialist staffing levels
  • Investment allocation to key Medical Affairs sub-functions

KEY METRICS
  • Do you have clinical specialists on staff?
  • To which function do your clinical specialists belong?
  • How valuable are the listed external activities which may be led by clinical specialists to support a medical device product launch?
  • How valuable are the listed internal activities which may be led by clinical specialists to support a medical device product launch?
  • Are clinical specialists incentivized at your organization?
  • What is the approximate total number of patients and procedures in the United States per year that meet the criteria for treatment with your medical device product?
  • Approximately how many MSLs vs. clinical specialists does your organization have on staff in support of your product?
  • What is the approximate launch investment that is allocated to each of the listed Medical Affairs sub-function during each time period?

SAMPLE KEY FINDINGS
  • The Role of Clinical Specialists:
    • 71% of device firms have clinical specialists on staff. Clinical specialists are especially useful during the launch of a breakthrough product, where they can train therapeutic area end-users on how to properly and safely use a new treatment.
    • Clinical specialists may belong to several different functions: Medical Affairs (at 42% of companies), clinical (27%), sales (21%), and even marketing and business units.
METHODOLOGY

Best Practices, LLC engaged 32 Medical Affairs leaders from 25 leading medical device companies in this research through a benchmarking survey. Five Medical Affairs executives were engaged in deep-dive interviews to capture additional insights.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Medical Device; Biotech; Manufacturing; Consumer Products; Biopharmaceutical; Clinical Research; Laboratories; Diversified


Companies Profiled:
Abbott; AcelRx; Alcon; Alcresta Therapeutics; Allergan; Astellas; Bausch + Lomb; Bayer; Boston Scientific; Ferring Pharmaceuticals; GE Healthcare; Gedeon Richter ; GRAIL; Innocoll; Irrimax Corporation; Medtronic; Merck; Nobel Biocare; Novartis; Nutricia; Roche Diagnostics; Sanofi; STERIS; Terumo Corporation; W.L. Gore and Associates

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.